These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32384949)

  • 1. Preparation of Programmed Death-Ligand 1 Antibody Nanoparticles and Their Lung Cancer Targeting Therapeutic Effects.
    Xing J; Xin B; Xia H
    J Nanosci Nanotechnol; 2020 Oct; 20(10):6033-6039. PubMed ID: 32384949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of Programmed Cell Death-Ligand 1 Antibody Nanoparticles Based on Nude Mouse Model and Its Therapeutic Effect on Lung Cancer.
    Wei L; Yu F; Meng Y
    J Nanosci Nanotechnol; 2021 Feb; 21(2):895-902. PubMed ID: 33183421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.
    Xu S; Cui F; Huang D; Zhang D; Zhu A; Sun X; Cao Y; Ding S; Wang Y; Gao E; Zhang F
    Int J Nanomedicine; 2019; 14():17-32. PubMed ID: 30587982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
    Li D; Wang X; Yang M; Kan Q; Duan Z
    Exp Cell Res; 2019 Jul; 380(1):20-28. PubMed ID: 30904483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upconversion nanoparticle-based fluorescence resonance energy transfer sensing of programmed death ligand 1 using sandwich epitope-imprinted polymers.
    Lee MH; Lin CC; Thomas JL; Chang YH; Chen CY; Lin CY; Wang TL; Lin HY
    Biosens Bioelectron; 2024 Feb; 246():115889. PubMed ID: 38043301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer.
    Yu X; Wu H; Hu H; Dong Z; Dang Y; Qi Q; Wang Y; Du S; Lu Y
    Drug Deliv; 2020 Dec; 27(1):100-109. PubMed ID: 31870183
    [No Abstract]   [Full Text] [Related]  

  • 8. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
    Hu W; Ma Y; Zhao C; Yin S; Hu H
    Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway].
    Zhu H; Liu D; Deng S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Oct; 37(10):891-896. PubMed ID: 34670665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Small Cyclic Peptide-Based
    Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
    Shen N; Yang C; Zhang X; Tang Z; Chen X
    Acta Biomater; 2021 Nov; 135():543-555. PubMed ID: 34400305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles.
    Pham LM; Poudel K; Ou W; Phung CD; Nguyen HT; Nguyen BL; Karmacharya P; Pandit M; Chang JH; Jeong JH; Ku SK; Yong CS; Choi HG; Kim JO
    Int J Pharm; 2021 Aug; 605():120816. PubMed ID: 34161810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
    Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
    J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of different levels of soluble PD-L1 protein on the growth of Lewis lung cancer transplanted tumor.
    Yang KN; Han W; Qin YJ; Chen LN
    J Biol Regul Homeost Agents; 2019; 33(2):537-542. PubMed ID: 30972999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
    Jiang K; Zou H
    Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
    Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
    Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.